Pilot Study of l-Selenomethionine in Prostate Cancer Patients Scheduled to Undergo Radical Prostatectomy

Closed

Phase

Accrual

100%

Published

Abbreviated Title

GU/Prostate

Activated

06/15/1999

Closed

06/01/2001

Treatment

Selenium

Eligibility Criteria Expand/Collapse

Pt must have histologically confirmed prostate adenocarcinoma. Pt must be scheduled to undergo prostatectomy not less than 14 nor more than 31 days after randomization. Pts who have taken greater than 50 mcg of selenium for greater than/equal 3 consecutive days within one month prior to registration are not eligible. Pts must agree to no selenium supplementation while on study. Pts rec'g thyroid supplementation are not eligible. Pt must agree to specimen submission per Section 15. Pts w/ history of malignancies are eligible if they are not currently rec'g tx and have completed tx at least 24 hours prior to reg. Pts must not begin treatment while on this study.

CANCER CONTROL CREDIT: 0.0
TREATMENT CREDIT: 1.0

Publication Information Expand/Collapse

2006

Selenium accumulation in prostate tissue during a randomized controlled short-term trial of I-selenomethionine: a Southwest Oncology Group study

AL Sabichi;JJ Lee;RJ Taylor;IM Thompson;BJ Miles;CM Tangen;LM Minasian;LL Pisters;JR Caton;JW Basler;SP Lerner;DG Menter;JR Marshall;ED Crawford;SM Lippman Clinical Cancer Research 12(7):2178-2184

2002

Selenium accumulates in prostate tissue of prostate cancer patients after short-term administration of selenomethlonine.

AL Sabichi;JJ Lee;RJ Taylor;IM Thompson Jr;BJ Miles;JW Basler;LL Platera;M Wargo;D Menter;CM Tangen;ED Crawford;SM Lippman Proc of the American Association for Cancer Research 43:1007(#4993)